2 Gansevoort Street
9th Floor
New York, NY 10014
United States
212-554-4484
http://www.tgtherapeutics.com
Sector: Healthcare
Industry: Biotechnology
Full Time Employees: 104
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Michael S. Weiss | Exec. Chairman, CEO & Pres | N/A | N/A | 1966 |
| Mr. Sean A. Power CPA | CFO, Corp. Sec. & Treasurer | 435.84k | N/A | 1982 |
| Jenna Bosco | VP of Investor Relations & Sr. VP of Corp. Communications | N/A | N/A | N/A |
| Mr. Adam Waldman | Chief Commercial Officer | N/A | N/A | N/A |
TG Therapeutics, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases in the United States. It develops TG-1101 (ublituximab), a chimeric, glycoengineered monoclonal antibody that targets an epitope on the CD20 antigen found on the surface of B-lymphocytes developed to aid in the depletion of circulating B-cells; and TG-1101 in combination with TGR-1202 for relapsed/refractory chronic lymphocytic leukemia. The company also develops TGR-1202, an orally available phosphoinositide-3-kinase delta inhibitor with nanomolar potency to the delta isoform and high selectivity over the alpha, beta, and gamma isoforms, as well as for hematologic malignancies. In addition, it develops a pre-clinical program to develop interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors; bromodomain and extra terminal (BET) inhibitor program for cancer treatment; and anti-PD-L1 and anti-GITR antibody research programs that are in pre-clinical development stage in the field of hematological malignancies. The company has license agreements with LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, and Ildong Pharmaceutical Co. Ltd. for the development and commercialization of TG-1101 (ublituximab); Rhizen Pharmaceuticals, SA for the development and commercialization of TGR-1202; Ligand Pharmaceuticals Incorporated for the development and commercialization of IRAK4 inhibitor technology; Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs; and Jubilant Biosys for the development and commercialization of BET inhibitor program. TG Therapeutics, Inc. was incorporated in 1993 and is headquartered in New York, New York.
TG Therapeutics, Inc.’s ISS Governance QualityScore as of February 1, 2019 is 10. The pillar scores are Audit: 2; Board: 10; Shareholder Rights: 4; Compensation: 10.